tiprankstipranks
Trending News
More News >
Haw Par Corporation Limited (SG:H02)
SGX:H02
Advertisement

Haw Par (H02) AI Stock Analysis

Compare
28 Followers

Top Page

SG

Haw Par

(SGX:H02)

Rating:74Outperform
Price Target:
S$14.00
â–²(10.58%Upside)
Haw Par's stock demonstrates a strong overall position, driven by robust financial performance and an attractive valuation. The company's solid profitability and minimal leverage are significant strengths. However, caution is advised due to technical indicators suggesting the stock may be overbought. The absence of earnings call data and notable corporate events did not influence the score.

Haw Par (H02) vs. iShares MSCI Singapore ETF (EWS)

Haw Par Business Overview & Revenue Model

Company DescriptionHaw Par Corporation Limited (H02) is a Singapore-based company with a diverse portfolio spanning several sectors, including healthcare, leisure, and property. The company is renowned for its flagship brand, Tiger Balm, a leading analgesic product used for pain relief and wellness. Besides healthcare, Haw Par's operations extend to owning and managing leisure properties and investing in strategic real estate assets.
How the Company Makes MoneyHaw Par generates revenue primarily through its healthcare segment, with Tiger Balm products contributing significantly to its earnings. The brand's global presence and wide range of products, such as ointments, plasters, and muscle rubs, ensure a steady revenue stream. Additionally, the company profits from its leisure business, which includes the management and operation of tourist attractions and aquariums. Haw Par also earns income through its property investments, which provide rental income and the potential for capital appreciation. Strategic partnerships and licensing agreements further enhance the company's financial performance by expanding its market reach and product offerings.

Haw Par Financial Statement Overview

Summary
Haw Par exhibits robust financial health with strong profitability and minimal leverage. The company maintains a high net profit margin of 93.22% and a substantial EBIT margin of 26.07%. While the balance sheet is notably strong with a low debt-to-equity ratio of 0.01, slight challenges are noted in cash flow generation, as operating cash flow has declined slightly compared to the previous year.
Income Statement
78
Positive
Haw Par demonstrates a strong income statement with consistent revenue growth, evidenced by a 5.51% increase in the latest year. The company maintains robust profitability metrics with a high net profit margin of 93.22% and a substantial EBIT margin of 26.07%. These indicators showcase Haw Par's effective cost management and revenue generation capabilities within the industry.
Balance Sheet
85
Very Positive
Haw Par's balance sheet is notably strong, featuring an exceptionally low debt-to-equity ratio of 0.01, highlighting minimal leverage and financial stability. The company's equity ratio of 97.00% reflects a solid capital structure, which is supported by high stockholders' equity. These factors contribute to the company's ability to sustain operations and invest in growth opportunities.
Cash Flow
72
Positive
Haw Par's cash flow statement is positive, with a stable free cash flow and a reasonable free cash flow to net income ratio of 0.22. However, a slight decline in operating cash flow compared to the previous year indicates potential challenges in cash generation from core operations. The company's overall cash reserves remain strong, providing a buffer to support ongoing activities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue244.82M232.06M182.09M141.18M111.03M
Gross Profit134.09M134.89M98.57M73.64M48.83M
EBITDA250.11M233.49M49.06M31.16M20.47M
Net Income228.27M216.57M148.32M110.10M119.77M
Balance Sheet
Total Assets4.28B3.59B3.65B3.28B2.95B
Cash, Cash Equivalents and Short-Term Investments3.93B3.21B334.27M596.23M554.41M
Total Debt36.30M28.48M29.20M762.00K892.00K
Total Liabilities128.47M117.17M101.41M72.08M64.00M
Stockholders Equity4.15B3.48B3.55B3.21B2.89B
Cash Flow
Free Cash Flow50.33M54.92M21.21M14.46M17.49M
Operating Cash Flow53.79M62.68M40.94M18.84M25.03M
Investing Cash Flow199.82M258.00M-261.58M87.52M138.09M
Financing Cash Flow-82.79M-79.30M-38.07M-65.11M-73.80M

Haw Par Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.66
Price Trends
50DMA
11.96
Positive
100DMA
11.78
Positive
200DMA
10.97
Positive
Market Momentum
MACD
0.18
Negative
RSI
63.78
Neutral
STOCH
87.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:H02, the sentiment is Positive. The current price of 12.66 is above the 20-day moving average (MA) of 12.30, above the 50-day MA of 11.96, and above the 200-day MA of 10.97, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 63.78 is Neutral, neither overbought nor oversold. The STOCH value of 87.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:H02.

Haw Par Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
SGH02
74
Outperform
$2.80B12.286.02%6.19%5.50%5.41%
SGBSL
66
Neutral
$1.92B30.456.02%2.45%6.30%-30.93%
63
Neutral
S$1.60B3.732.87%4.32%17.84%20.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SG:H02
Haw Par
12.66
3.56
39.20%
SG:BSL
Raffles Medical Group
1.02
0.03
2.51%

Haw Par Corporate Events

Haw Par Corporation Convenes 56th Annual General Meeting
May 19, 2025

Haw Par Corporation Limited held its 56th Annual General Meeting at Parkroyal on Beach Road in Singapore, with key members of the Board of Directors and shareholders in attendance. The meeting commenced with a quorum and was chaired by Mr. Wee Ee Chao, focusing on the formal proceedings as per the circulated notice.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 02, 2025